Predictive Oncology Stock (NASDAQ:POAI), Analyst Ratings, Price Targets, Predictions

The latest price target for Predictive Oncology (NASDAQ: POAI) was reported by HC Wainwright & Co. on June 30, 2021. The analyst firm set a price target for $5.00 expecting POAI to rise to within 12 months (a possible 204.88% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Predictive Oncology (NASDAQ: POAI) was provided by HC Wainwright & Co., and Predictive Oncology initiated their buy rating.

There is no last upgrade for Predictive Oncology.

There is no last downgrade for Predictive Oncology.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Predictive Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Predictive Oncology was filed on June 30, 2021 so you should expect the next rating to be made available sometime around June 30, 2022.

While ratings are subjective and will change, the latest Predictive Oncology (POAI) rating was a initiated with a price target of $0.00 to $5.00. The current price Predictive Oncology (POAI) is trading at is $1.64, which is within the analyst’s predicted range.